In the News

Share
1731 News Items found
Finding
Gloved hands hold a pipette over two bottles of pink solution.
The Gut Microbiome and Cancer: MSK Researchers Present New Findings
Research led by Josie Robertson Investigator Karuna Ganesh provided clues that microbiomes might explain the increase in colorectal cancer among younger patients.
MSK computational biologist Henry Walch
Why Is Colorectal Cancer in African Americans Hard To Treat? One Reason Is Genetics
African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.
MSK medical oncologist and bladder cancer specialist Jonathan Rosenberg
New Metastatic Bladder Cancer Therapy Approved by FDA: Enfortumab Vedotin (Padcev)
A powerful therapy called an antibody-drug conjugate is approved for more people with metastatic bladder cancer.
Mobile Health Unit
Education and Care on Wheels: MSK’s Mobile Health Unit Serves Communities across New York Metro Area
MSK’s Mobile Health Unit provides health education, screening, and navigation services to underserved communities in the New York metro area.
Cassidy Cobbs
Transgender Visibility: Meet MSK Cancer Research Staffer Cassidy Cobbs
Cassidy Cobbs is many things: a valued colleague who works at the Sloan Kettering Institute; a doting parent to a pit bull named Mando; a beloved sibling; and a passionate baseball fan, who memorized the stats of former player, Ryne Sandberg, at the age of 5. What Cassidy is not is someone who identifies as either a man or a woman.
Microscopy image showing a quiescent cluster of lung adenocarcinoma tumor cells with low STING expression.
MSK Scientists Identify Potential New Strategy Against Metastasis
A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.
In the Clinic
Dr. Carol Aghajanian
For Advanced Endometrial Cancer, Chemotherapy Plus Immunotherapy Improves Outcomes
New research published in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves outcomes in people with advanced endometrial cancer. The phase 3 study was overseen by MSK gynecologic medical oncologist Carol Aghajanian.
A scientist pipetting in a lab
MSK Research Highlights, March 9, 2023
New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.
MSK physician-scientists Michele Sadelain, Isabelle Riviere, and Jae Park
Testing CRISPR-Edited CAR T Cell Therapy in Lymphoma Clinical Trial
A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.
SKI biomedical engineer Dr. Daniel Heller
Getting Drugs Across the Blood-Brain Barrier Using Nanoparticles
Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.